5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors

US8088780B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• Gunnar Nordvall · Gately Drive, SE
• Colin Ray · Gately Drive, SE
• Tobias Rein · Gately Drive, SE
• Daniel Sohn · Gately Drive, SE

Key dates

• Filing date: Apr 3, 2006
• Grant date: Jan 3, 2012
• Expiry date: Apr 3, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.